Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Hypotension Treatment Market size was valued at USD 950.3 million in 2024 and is anticipated to surpass USD 2.47 billion by 2037, registering a CAGR of 8.3% during the forecast timeline i.e. 2025-2037. In 2025, the industry size of hypotension treatment is evaluated at USD 1.02 billion.
The hypotension treatment market growth is dynamically altered by both epidemiologic transition and clinical innovation. Increasing proportions of elderly citizens within the populations of the world and increasing loads of pre-existing chronic diseases such as diabetes and cardiovascular disease have necessitated increased needs for effective treatment of hypotension. For instance, in October 2024, according to the published data from WHO, there will be 1.4 billion persons over 60 globally by 2030, up from 1 billion in 2020, and by 2050, that number is expected to double to 2.1 billion. In addition to that, as per CDC data, 702,880 persons lost their lives to heart disease in 2022, that's one out of every five fatalities. The most prevalent kind of cardiovascular disease in 2022 was coronary heart disease 2022, which claimed 371,506 lives.
Increasing numbers of these patients have propelled mass-level R&D at both non-pharmacologic and pharmacotherapeutic levels. Furthermore, in January 2023, AstraZeneca has entered into a definitive agreemenr with CinCor Pharma, Inc. (CinCor). This acquisition gave global rights to AstraZeneca for baxdrostat, a new aldosterone synthase inhibitor being developed for blood pressure lowering. Moreover, increasing attention is being devoted to the use of adjunctive non-pharmacologic interventions such as lifestyle change, compression therapy, and structured patient education to maximize therapeutic yield and perhaps curtail pharmacologic dependency. This shift towards patient-specific therapy is expected to bolster the market growth during the stipulated timeframe.
Hypotension Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Novel drug developments: Pharmaceutical development is increasing as one of the primary forces behind the hypotension treatment market growth. Pharmaceutical research is focused on drugs specific to pathophysiologic mechanisms, thus more targeted and potent. For instance, in October 2024, The National Science Foundation (NSF) has awarded a USD 1 million follow-up grant to Dynocardia. This funding enhanced the company's innovative motion-artifact mitigation technology, enabling precise and continuous monitoring of BP and other vital signs in real-world situations. Hence, non-pharmacologic therapy emphasis is one of the strongest drivers leading to more comprehensive patient care.
- Emphasis on non-pharmacological interventions: The hypotension treatment market is driven by the lifestyle interventions, from least significant enhanced fluid and salt load, exercise, and posture, are now well-established candidates for first-line treatment. For instance, in February 2022, cardiologists have encountered hypotension with accompanying unpleasant symptoms in their daily work and lives. The research found that orthostatic hypotension affects roughly 3–26% of hypertensive individuals, and that the probability rises with age. Thus, this focus on empowering patients to manage their condition with non-drug interventions, alongside increased awareness of orthostatic hypotension, is a key market driver.
Challenges
- Limited clinical data: The lack of data within the hypotension treatment market makes it complex to develop evidence-based clinical practice guidelines and therefore, creates therapeutic decision-making uncertain. Heterogeneity of orthostatic hypotension and variable presentation by age groups and comorbidities are those which need broader, longer duration trials for the assessment of efficacy as well as safety of pharmacological as well as non-pharmacological interventions. In spite of the barrier, rising incidence of orthostatic hypotension with rising population aging globally is one of the key growth drivers that pose a critical need to bridge the gap in research data available.
- Heterogeneity of hypotension: Intrinsic heterogeneity within the hypotension treatment market is a major barrier in rendering diagnosis and treatment strategy. Incompleteness of uniform clinical presentation and manifestation of crossing symptoms also add to the diagnostic difficulty, making patient stratification inaccurate and targeted therapy problematic. Meeting this formidable challenge, the world's increased aging population as a prime factor for growth adds more to hypotensive disorders' frequency that require more advanced diagnostic devices and professional treatment intervention in order to treat multilateral manifestations of hypotension.
Hypotension Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.3% |
|
Base Year Market Size (2024) |
USD 950.3 million |
|
Forecast Year Market Size (2037) |
USD 2.47 billion |
|
Regional Scope |
|
Hypotension Treatment Segmentation
End user (Diagnostic Centers, Home Care, Hospitals & Clinics)
Based on the end user, the diagnostic centers segment is set to hold hypotension treatment market share of more than 49.4% by 2037, as it offers diagnostic technology of a highly specialized nature. In addition, greater focus on preventive screening and early detection continues to impose burden on demand for such facilities as part of hypotension management. For instance, in February 2024, 323 participants from BP-CHECK in adults with elevated blood pressure were recruited from 12 primary care clinics of an integrated health care system in Washington State between 2017 and 2019. As per the conducted survey, a post hoc analysis of these participants based on 24-hour ambulatory blood pressure monitoring stated that all 323 participants had a positive diagnostic test result for hypertension and were monitored for six months.
Product (Blood Pressure Transducers, Sphygmomanometers, Blood Pressure Devices)
The blood pressure transducers segment is anticipated to dominate the hypotension treatment market throughout the projected timeframe as their all-around relevance to real-time measurement of hemodynamics essential to proper diagnosis and individualized treatment of hypotensive attacks. For instance, in November 2024, an enhanced wearable ultrasonic patch for continuous, noninvasive blood pressure monitoring has been created by a group of researchers at the University of California, San Diego. Since the gadget is the first wearable ultrasound blood pressure sensor to go through extensive and thorough clinical validation on more than 100 patients, their study represents a significant milestone.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportHypotension treatment Industry - Regional Synopsis
North America Market Statistics
North America in hypotension treatment market is expected to capture around 49.4% revenue share by the end of 2037. This growth can be attributed to the improved technology that renders utmost efficacy in diagnosis such diseases timely and helps in tailoring the specified medication. Moreover, the increased healthcare spending, growing public knowledge of illnesses, and the availability of treatments boost the market demand.
In the U.S. hypotension treatment market is likely to unveil lucrative growth opportunities owing to the government regulations and approvals for novel therapeutic drugs to improve the patient’s outcome. For instance, in December 2021, The U.S. FDA granted Directed Systems Limited 510(k) approval to install a new version of the Hypotension Decision Assist (HDA) software on an Advantech medical tablet with networking features. Hence, the market is set to flourish during the projected timeline.
Canada hypotension treatment market is exponentially increasing its footprints through strategical investments in manufacturing and crafting conducive healthcare infrastructure. For instance, in January 2025, AstraZeneca announced that it will spend USD 570 million in Canada. The investment helped finance the relocation to a bigger and state-of-the-art infrastructural setting in Ontario's Greater Toronto Area (GTA). The increased investment in Canada helped AstraZeneca reach its global goals of bringing 20 new medications to patients worldwide by 2030 and reaching USD 80 billion in total revenue.
Asia Pacific Market Analysis
The hypotension treatment market in Asia Pacific is likely to witness fastest growth during the stipulated timeframe. The medication used for tretaing hypotension is gaining traction due to their use in enhancing the quality of life for patients with diseases such as diabetes, Parkinson's disease, and aging-related disorders where autonomic dysfunction. In addition, hospitals, specialized clinics, and home care settings are all included in the end-use scope within the regionbecause they serve a range of patient needs that call for varying degrees of medical intervention.
In India hypotension treatment market is likely to witness a robust growth owing to strengthening of partnerships between companies to prevent the instances of cardiovascular diseases. For instance, in August 2023, in order to increase awareness about taking blood pressure readings at home starting at age 18, Glenmark Pharmaceuticals Limited has partnered with OMRON Healthcare India, to find solutions for cardiovascular disease management.
The hypotension treatment market in China is mostly driven by robust governmental support. For instance, in February, 2023, the 'Healthy China 2030' effort was expected to significantly enhance public health, with a focus on increasing the control rate of hypertension. Through extensive healthcare changes and national public health initiatives, this program focuses on increasing awareness, encouraging prevention, and improving the treatment of hypertension. For instance, Hanvon introduced a novel blood pressure monitor in April 2024 that uses the Korotkoff-Sound method, which is typically used in clinical settings, to provide increased accuracy.
Companies Dominating the Hypotension treatment Landscape
- A & D Medical
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Schiller AG
- American Diagnostic Corporation
- Spacelabs Healthcare
- OMRON Corporation
- Amgen
- Amneal Pharmaceuticals LLC
- Apotex, Inc.
- Chelsea Therapeutics
- F. Hoffman-La Roche
- H. Lundbeck A/S
- Mylan Inc.
The ecosystem in the hypotension treatment market is highly competitive due to presence of large pharmaceutical companies and emerging companies striving to achieve maximum patient outcome and better healthcare. For instance, in March 2025, a definitive agreement has been reached for Boston Scientific Corporation to purchase SoniVie Ltd., that created the TIVUSTM Intravascular Ultrasound System. In order to treat a number of hypertensive illnesses, including renal artery denervation (RDN) for hypertension, the TIVUS system is an experimental device that denervates the nerves around blood vessels.
Here's the list of some key players:
In the News
- In February 2025, Teva Pharmaceuticals unveiled that the FDA has approved the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I in adults.
- In May 2023, Theravance Biopharma, Inc. announced that the US FDA granted orphan drug designation status to ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
Author Credits: Radhika Pawar
- Report ID: 7365
- Published Date: Mar 21, 2025
- Report Format: PDF, PPT
